share_log

Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%

kopsource ·  Apr 20, 2023 04:43

Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 620,700 shares, an increase of 30.3% from the March 15th total of 476,200 shares. Based on an average daily volume of 738,300 shares, the short-interest ratio is presently 0.8 days.

Innovation Pharmaceuticals Stock Down 10.0 %

Shares of OTCMKTS:IPIX traded down $0.00 during midday trading on Wednesday, hitting $0.02. The stock had a trading volume of 203,046 shares, compared to its average volume of 546,743. The stock has a 50 day moving average price of $0.02 and a two-hundred day moving average price of $0.02. Innovation Pharmaceuticals has a 1 year low of $0.01 and a 1 year high of $0.06.

Get Innovation Pharmaceuticals alerts:

About Innovation Pharmaceuticals

(Get Rating)

Innovation Pharmaceuticals, Inc is a clinical stage biotechnology company. It engages in developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The firm's lead cancer compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers.

Read More

  • Get a free copy of the StockNews.com research report on Innovation Pharmaceuticals (IPIX)
  • ASML Reports Massive Growth, Management Points To Sluggish 2023
  • Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
  • Mullen Automotive: Is The Bloom Off The Rose?
  • Diversified Abbott Laboratories Could Reverse And Move Higher
  • Okta Reversal In Progress While Catalysts Approach

Receive News & Ratings for Innovation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment